These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 32705213)

  • 1. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
    Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
    Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
    Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
    J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
    Xue B; Li S; Jin X; Liu L
    BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated bioinformatics analysis for differentially expressed genes and signaling pathways identification in gastric cancer.
    Yang C; Gong A
    Int J Med Sci; 2021; 18(3):792-800. PubMed ID: 33437215
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
    Zhang M; Luo SC
    Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
    Zhan SJ; Liu B; Linghu H
    Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
    Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
    Gui T; Yao C; Jia B; Shen K
    PLoS One; 2021; 16(6):e0253136. PubMed ID: 34143800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
    Zuo L; Li X; Tan Y; Zhu H; Xiao M
    J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments.
    Zhang T; Guo J; Gu J; Wang Z; Wang G; Li H; Wang J
    Oncol Rep; 2019 Jan; 41(1):279-291. PubMed ID: 30542696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
    Li Y; Li L
    J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
    Zou J; Yin F; Wang Q; Zhang W; Li L
    Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.
    Wang H; Yu Y; Chen C; Wang Q; Huang T; Hong F; Zhu L
    Mol Med Rep; 2015 Aug; 12(2):2503-10. PubMed ID: 25955318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
    Sun T; Bi F; Liu Z; Yang Q
    Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of hub genes associated with cisplatin-resistance in ovarian cancer and screening of therapeutic drugs through bioinformatics and experimental validation.
    Zhu Y; Chen X; Tang R; Li G; Yang J; Hong S
    J Ovarian Res; 2024 Jul; 17(1):142. PubMed ID: 38987777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
    Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
    Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
    Shang M; Zhang L; Chen X; Zheng S
    Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Integrated Microarray Analysis Reveals Significant Diagnostic and Prognostic Biomarkers in Pancreatic Cancer.
    Yang ZQ; Liu YJ; Zhou XL
    Med Sci Monit; 2020 Apr; 26():e921769. PubMed ID: 32235821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
    Zhang L; Sun L; Zhang B; Chen L
    Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 and RIF1 overexpression induces resistance of epithelial ovarian cancer to cisplatin-based chemotherapy.
    Sad LMAE; Mohamed DA; Elanwar NM; Elkady A
    J Cancer Res Ther; 2021; 17(6):1454-1461. PubMed ID: 34916377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.